Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bill Gates On Vaccine Distribution Challenges, Overcoming Vaccine Hesitancy

Executive Summary

The public health advocate and billionaire philanthropist raised issues about how a mass COVID-19 vaccination effort is being handled so far in the US, speaking at the Stat Summit.

You may also be interested in...



Pfizer Is Ready To File Vaccine, With More Good News On Over-65s Efficacy

Pfizer is moving swiftly towards an emergency use approval filing, with Moderna not far behind.

Pfizer Pilots COVID-19 Immunization Plan In Four States As ‘Dry Run’

The company's Phase III COVID-19 vaccine trial has reached the needed safety data required for filing an emergency use authorization with the FDA, Bourla confirmed at the Stat Summit.

A Biopharma A-List Lineup Aims To Tackle Complex Manufacturing At Resilience

Resilience has raised $800m to develop new technologies to manufacture complex drugs including vaccines, cell therapies and gene therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134882

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel